An FDA panel's provisory vote of confidence for a drug from Sprout Pharmaceuticals Inc. that could become the first ever therapy for hypoactive sexual desire disorder (HSDD) in premenopausal women lifted shares of a would-competitor: Palatin Technologies Inc., which is advancing its candidate through phase III trials.